For individuals with severe alopecia areata who fail to respond or experience limited long-term success with initial treatment, alternative therapeutic strategies are essential. Recent research suggests that switching between Janus kinase inhibitors may be a viable option for these patients.
The efficacy and safety of switching between oral Janus kinase inhibitors were evaluated in a retrospective study involving 108 patients from six sites across the United States. The patients had been diagnosed with severe alopecia areata, as defined by the Alopecia Areata Scale (AASc), and had undergone treatment for at least six months.
The mean age of the patients was approximately 39 years, with a female predominance and predominantly White population. The median duration of alopecia areata was 12 years, with nearly half the patients exhibiting universalis type and an average Severity of Alopecia Tool (SALT) score of 78 at baseline.
Most patients had initially been treated with tofacitinib, with a mean daily dose of 12 mg for approximately three years. The treatment response was evaluated using the SALT score, with symptom improvement and reduced scores indicating effective treatment.
The findings of this study underscore the potential benefits of switching between Janus kinase inhibitors in select patients with refractory alopecia areata, particularly those with a history of responsiveness to prior oral treatment.
Two-thirds of patients exhibited symptom improvement with their initial Janus kinase inhibitor therapy, with nearly 36% achieving a SALT score of 20 or less and over 27% attaining a score of 10 or less. The response rates varied among the different Janus kinase inhibitors used, with tofacitinib demonstrating the highest proportion of improvement and baricitinib exhibiting the lowest.
Interestingly, patients who switched from tofacitinib had higher treatment response rates compared to those switching from baricitinib. Among patients who switched to a third Janus kinase inhibitor, nearly 53% achieved a SALT score of 20 or less and over 38% attained a score of 10 or less.
The study's findings suggest that prior responsiveness to initial Janus kinase inhibitor treatment is the most significant predictor of response to subsequent therapy. Additionally, having a family history of alopecia areata tended to inversely relate with response to second-line treatment, although this association was not statistically significant.
Common adverse events associated with Janus kinase inhibitors included hypercholesterolemia and acne.
The study is limited by the heterogeneity among treatment dosing and trajectories.
The results of this research support the clinical utility of switching between Janus kinase inhibitors in select patients with refractory alopecia areata, particularly those who have responded to prior oral treatment.